Effect of pravastatin on cerebral infarcts and white matter lesions.
The authors examined the effect of pravastatin 40 mg daily on the progression of ischemic brain lesions using repeated brain MRI. After a mean treatment period of 33 months, there was an increase in total ischemic lesion load of 1.1 cm3 (p < 0.001) in the 270 placebo-treated subjects and 1.1 cm3 (p < 0.001) in the 265 pravastatin-treated subjects. There was no difference between the two treatment groups (p = 0.73).
ten Dam
V H
VH
Department of Internal Medicine, Leiden University Medical Center, The Netherlands. V.H.ten_Dam@lumc.nl
van den Heuvel
D M J
DM
van Buchem
M A
MA
Westendorp
R G J
RG
Bollen
E L E M
EL
Ford
I
I
de Craen
A J M
AJ
Blauw
G J
GJ
D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D018450:Disease Progression; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D002537:Intracranial Arteriosclerosis / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control; D008279:Magnetic Resonance Imaging; D008297:Male; D009413:Nerve Fibers, Myelinated / Q000187:drug effects* / Q000473:pathology; D017035:Pravastatin / Q000008:administration & dosage*; D011446:Prospective Studies; D013687:Telencephalon / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D017211:Treatment Failure
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin